Brooks Laboratories
BROOKS NSE
Brooks Laboratories
HealthcareNSE: BROOKS BSE: 533543 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹186 Cr
Volatility
Moderate
P/E Ratio
14.63
EBITDA
₹8.20 Cr
Return on Equity
20.04%
Debt to Equity
0.07
Book Value
₹41.64
52W High
₹163.9
52W Low
₹36.3
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 26.6% CAGR over last 5 years
Weaknesses
5- The company has delivered a poor sales growth of 2.11% over past five years.
- Company has a low return on equity of -2.02% over last 3 years.
- Contingent liabilities of Rs.123 Cr.
- Earnings include an other income of Rs.13.0 Cr.
- Promoter holding has decreased over last 3 years: -13.8%
Growth Rate
Revenue Growth
4.2% lower than
3Y
Net Income Growth
-346% lower than
3Y
Cash Flow Change
253% higher than
3Y
ROE
-297% lower than
3Y
ROCE
-332% lower than
3Y
EBITDA Margin (Avg.)
35.67% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.7 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| Expenses | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.2 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.3 |
| Operating Profit | -3.91 | -1.1 | -3.37 | -9.53 | -1.92 | -3.41 | -1.5 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 |
| OPM % | -24.9% | -4.52% | -15.49% | -53.78% | -10.71% | -16.4% | -7.31% | -5.4% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% |
| Other Income | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.2 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 |
| Interest | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.3 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.44 | 0.44 | 0.43 | 0.46 | 0.4 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| PBT | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.5 | 1.53 | -1.79 |
| Tax % | 0% | 0% | 0.78% | 0% | 0% | 0% | 0% | 13.95% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.5 | 1.52 | -1.79 |
| EPS in Rs | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.5 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 86 | 83 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 79 | 81 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 7 | 3 |
| OPM % | 0.7% | -16% | -47% | -22% | -10% | 8% | 3.1% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 20 | 13 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| PBT | -9 | -24 | -38 | -20 | -10 | 25 | 13 |
| Tax % | 115% | -19% | -19% | 0% | 2% | 0% | — |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 25 | 13 |
| EPS in Rs | -7.4 | -4.31 | -7.97 | -7.46 | -3.38 | 8.34 | 4.49 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 93 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 9 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 17 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 148 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 92 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 148 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 4 | -37 | -14 | -10 | 3 | 9 |
| Investing | -5 | -25 | 0 | 0 | -45 | -3 |
| Financing | 1 | 64 | 11 | 10 | 42 | 0 |
| Net Cash Flow | 0 | 2 | -3 | 0 | 0 | 7 |
| Free Cash Flow | -1 | -62 | -15 | -10 | 2 | 6 |
| CFO/OP | 1,519 | 261 | 48 | 56 | -26 | 131 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 | 69 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 | 77 |
| Days Payable | 233 | 159 | 165 | 97 | 90 | 80 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 | 59 | 66 |
| Working Capital Days | -85 | 34 | -37 | 34 | 43 | 34 |
| ROCE % | — | -16% | -30% | -25% | -10% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Brooks Laboratories insights
62 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Brooks Laboratories confirms it is not a large corporate for FY2026; outstanding borrowing was Rs 1.19 crore. 29 Apr - Brooks Laboratories confirms it is not a large corporate for FY2026; outstanding borrowing was Rs 1.19 crore.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Brooks Laboratories confirms it is not a large corporate for FY2026; outstanding borrowing was Rs 1.19 crore. 29 Apr - Brooks Laboratories confirms it is not a large corporate for FY2026; outstanding borrowing was Rs 1.19 crore.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Certificate under Regulation 74(5) of SEBI(DP) Regulation, 2018 for quarter ended 31st March 2026. 10 Apr - Certificate under Regulation 74(5) of SEBI(DP) Regulation, 2018 for quarter ended 31st March 2026.
4
Reply To Clarification Sought Vide Email Dated 1St April 2026 With Reference To Price Movement.
2 Apr - Brooks Laboratories clarifies no unpublished price-sensitive information and says share price movement is market-driven. 2 Apr - Brooks Laboratories clarifies no unpublished price-sensitive information and says share price movement is market-driven.
5
Clarification Sought from Brooks Laboratories Ltd
1 Apr - Exchange has sought clarification from Brooks Laboratories Ltd on April 1, 2026 with reference to significant movement in price, in order to ensure that investors … 1 Apr - Exchange has sought clarification from Brooks Laboratories Ltd on April 1, 2026 with reference to significant movement in price, in order to ensure that investors …
Frequently Asked Questions about Brooks Laboratories
What does Brooks Laboratories Ltd do?
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
Where is Brooks Laboratories Ltd (BROOKS) listed?
Brooks Laboratories Ltd trades as BROOKS on the NSE and under code 533543 on the BSE.
Which sector does Brooks Laboratories Ltd belong to?
Brooks Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Brooks Laboratories Ltd?
Brooks Laboratories Ltd has a market capitalisation of ₹186.17 Cr, which places it in the Small Cap band.
What is the PE ratio of Brooks Laboratories Ltd?
Brooks Laboratories Ltd trades at a PE ratio of 14.63, against a book value of ₹41.64 per share.
What is the 52-week high and low of Brooks Laboratories Ltd?
Over the last 52 weeks Brooks Laboratories Ltd has traded between ₹36.3 and ₹163.9.
What is the Return on Equity (ROE) of Brooks Laboratories Ltd?
Brooks Laboratories Ltd reported a return on equity of 20.04%. Its debt-to-equity ratio is 0.07.
Company Information
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
Website brookslabs.net
CEO Mr. Prashant Rathi
Employees 323
Listed 2011-09-05
Face Value ₹ 10
Issued Size 2,94,57,248
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BROOKS.md for Brooks Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.